Regulatory

Editor’s Note: On December 2, the European Food Safety Authority (EFSA; Parma, Italy) held a meeting in Amsterdam with the intention of clarifying its process of reviewing Article 13 and Article 14 health claims, specifically those concerning gut and immune health. The probiotics community was well represented at the meeting, which was led by members of EFSA’s Dietetic Products, Nutrition, and Allergies (NDA) panel. Below are reflections from the meeting from representatives of probiotics specialist Danisco A/S (Denmark).

Should drug and supplement companies be required to alert investors whenever any adverse-event report (AERs) over a product arises-in case an AER is predictive of a larger problem with the product that could devalue shareholder stocks?

BioAstin, the natural astaxanthin ingredient from Cyanotech Corp. (Kailua-Kona, HI), has been self-affirmed generally recognized as safe (GRAS) for use in food, beverages, and supplements, at a dose of 1.5 mg/serving.